The past two decades have witnessed remarkable progress in the therapeutic paradigm of MM with the introduction of immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti-CD38 antibodies (Abs) (2, 3). Here, CD38 is linked to Miyoshi myopathy.